In just over a week, the eyes of the world will fall on London as the city hosts the opening ceremonies for the 2012 Summer Olympics. Millions of people from around the globe will watch in awe as the world’s greatest athletes enthrall and inspire us, remind us of our common humanity and showcase the triumph of the human spirit as these amazing athletes push the limits of their physical capabilities.
Sadly, some competitors succumb to the tremendous pressure and strain of being a world-class athlete and the desire to win by turning to doping to enhance their performance. Doping not only creates an uneven playing field, it can jeopardize the health of the individual athlete and undermines respect for and the integrity of medical and athletic ethics as well as scientific innovation.
To help combat doping in sport, BIO is pleased to join with the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the World Anti-Doping Agency (WADA) to launch 2 FIELDS 1 GOAL: Protecting the Integrity of Science and Sport campaign. This campaign aims to achieve the goals of the Joint Declaration on Cooperation in the Fight against Doping in Sport (Joint Declaration), endorsed by BIO in 2011.
The campaign creates a framework of collaboration and encourages the voluntary cooperation of IFPMA and BIO member companies with WADA to readily identify compounds with the potential for misuse by athletes and to stop doping in sport. The campaign will allow for the sharing of information between participating companies and WADA in order to develop testing and detection methods to identify illegal or illicit use by athletes.
A critical part of this effort is the Points to Consider: Identification of Compounds with Potential for Doping Abuse and Sharing of Information with WADA (Points to Consider) booklet. This new resource provides biotechnology companies with practical guidelines to help identify compounds with sports-related doping potential before they come to market. The Points to Consider booklet also helps minimize misuse of compounds during clinical trials, and facilitate the sharing of information and collaboration on communications about medicines with known doping potential.
For a copy of the Points to Consider booklet and campaign materials, please visit www.ifpma.org/ethics/doping-in-sport.html.
And now, let the Games begin!